
Myovant Sciences (NYSE:MYOV) brought in sales totaling $54.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 193.85%, resulting in a loss of $63.45 million. Myovant Sciences collected $77.90 million in revenue during Q2, but reported earnings showed a $21.59 million loss.